Five Drugs, One Lever - What it means for the shopping decision

LONGEVITY LATEST ISSUE 24 · 19 AUGUST 2026

LONGEVITY LATEST · DEEP DIVE

Five Drugs, One Lever

Statins, ezetimibe, bempedoic acid and a fermented rice — four routes to one receptor, and why your arteries can't tell which one you took.

By Christian Thomsen · Companion to Issue 24 · 19 August 2026 · ~6-minute read

Three drugs, three unrelated targets. A statin works inside the liver cell, on an enzyme. Ezetimibe works in the lining of the small intestine, on a transporter. Bempedoic acid works two rungs further up the same synthesis chain as the statin, and only switches on in tissue carrying the enzyme that activates it.

You would expect three mechanisms that different to buy three different amounts of protection per unit of cholesterol removed. They don't. And the reason they don't is the single most useful fact in this field — it tells you which arguments about cholesterol drugs are worth having, and which are marketing.

The lever

Every cell in your body needs cholesterol, and the liver cell has two ways to get it: make it, or import it. It monitors its own internal supply continuously through a sensing system built around a protein called SREBP-2, and it adjusts. When internal cholesterol runs low, the cell manufactures more LDL receptors and pushes them out onto its surface.

Each of those receptors is a hand. It grabs an apoB-carrying particle out of the passing blood and pulls it inside. The number of hands on the liver's surface sets the rate at which particles leave your circulation, and that rate — not your diet, not the number printed on your last blood test — is what determines the concentration that ends up pressing against your artery walls.

Which reframes what a cholesterol drug is. It isn't something that removes cholesterol. It is something that persuades the liver it is running short, so that the liver puts out more hands.

Every drug in this issue is a different way of lying to the same cell about how much cholesterol it has.

A statin blocks HMG-CoA reductase and cuts internal manufacture. Ezetimibe blocks NPC1L1 in the gut and cuts imports — mostly not the cholesterol you ate, incidentally, but the far larger amount your own bile delivers and reabsorbs several times a day. Bempedoic acid blocks ATP-citrate lyase, two steps above the statin's target on the same chain. PCSK9 inhibitors come at it from the other end entirely: PCSK9 is the protein that tags used receptors for destruction, so blocking it means each hand gets recycled and reused instead of being thrown away.

Four interventions. One lever. A caveat worth noting: this is the main pathway, not the whole of lipid biology. Lp(a) is only partly cleared through these receptors, which is precisely why none of these drugs meaningfully lowers it — the point we left hanging at the end of last week's issue.

How we know it isn't just a nice story

The elegant test came from genetics rather than pharmacology. Some people inherit variants in NPC1L1 — ezetimibe's target — that leave them with slightly lower LDL cholesterol from birth. Others inherit variants in HMGCR, the statin's target. Those variants are dealt out at conception, independent of diet, income, exercise or anything else that wrecks an observational study.

Ference and colleagues used that to run a two-by-two factorial trial nature had already conducted: 108,376 people, 10,464 coronary events, sorted into four groups by which variants they carried. The NPC1L1 group had 2.4 mg/dL lower LDL cholesterol and 4.8% less coronary heart disease. The HMGCR group had 2.9 mg/dL lower and 5.3% less.

Per unit of cholesterol removed, the two were statistically indistinguishable. A separate analysis found the same for PCSK9 variants against HMGCR variants — odds ratios of 0.84 apiece per 10 mg/dL. Same lever, same result, regardless of which end you push.

There is a detail in that second study I find quietly persuasive. The PCSK9 group also carried a 6.1% higher risk of diabetes — the same off-target signature statins are criticised for. Even the side effect travels with the mechanism rather than the molecule, which is roughly the last thing you would expect if the drugs were doing genuinely different things.

The failures that prove the rule

If the receptor pathway is the thing that matters, then interventions which improve lipid numbers without durably reducing apoB particle count should fail. That is a falsifiable prediction, and the field has tested it expensively.

Niacin raises HDL and nudges LDL down; two large outcomes trials found no benefit on top of a statin. Fibrates move triglycerides and have never delivered convincingly in unselected populations. The first generation of CETP inhibitors produced spectacular HDL increases and no clinical benefit at all — one of them caused harm through an unrelated effect on blood pressure. Every one of those disappointments involved changing a lipid number without changing how many apoB particles were circulating.

I expected the exceptions to be the awkward part of this story. They turned out to be the confirming part.

What it means for the shopping decision

Three consequences fall out, and the third is the one that costs people money.

First, sequencing beats intensity. If a moderate statin and ezetimibe together produce the same particle reduction as a high-intensity statin alone, the receptor model says they should deliver the same outcome — and RACING found exactly that, with fewer people abandoning treatment. Two gentle levers, one result.

Second, the mechanism is not a feature you should pay extra for. Bempedoic acid is a genuinely clever molecule and costs forty-five times what atorvastatin costs. It earns that price for someone who cannot take a statin. For everyone else, the cleverness is buying a different route to the same receptor.

Third — and this is where the Hype Check comes back — “natural” is not a biological category. Monacolin K presses this lever because monacolin K is lovastatin. The liver cell has no mechanism for detecting whether a molecule arrived from a fermentation vat or a factory. What it can detect, and what actually matters to you, is the dose. And the dose is the one thing a supplement label doesn't reliably tell you.

The frontier

Three things worth watching. Oral PCSK9 inhibitors are in late-stage trials, which would move a receptor-recycling drug from injection to tablet. Inclisiran lowers LDL cholesterol for six months from a single dose, but its cardiovascular outcomes trials are still reading out — the 2026 guideline says so explicitly, and is right to wait. And a newer CETP inhibitor that does substantially lower apoB, unlike its predecessors, is in outcomes trials now. The receptor model predicts it should work. That is a real test, and I'd rather see it pass than assume it.

What this means for you

If I were designing a protocol from this evidence, it would be boringly simple and would disappoint anyone hoping for a stack.

Establish your ten-year risk. If treatment is indicated, start with a statin, because it is the cheapest way to move the lever and the best-documented. If you are not at target, add ezetimibe before escalating the statin dose — same destination, fewer people falling off the wagon. If you genuinely cannot tolerate a statin, and you have established that under blinded conditions rather than by assumption, bempedoic acid is a real option and worth its price. And stop shopping for mechanism. The artery is not counting mechanisms. It is counting particles, and multiplying by years.

The cheapest item on that list costs about a pound a month. The expensive part was never the drug.

Sources and further reading

1. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower LDL cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552–1561. PMID: 25770315 — 108,376 participants, 10,464 CHD events; effect per unit lower LDL-C indistinguishable between targets.

2. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144–2153. PMID: 27959767 — near-identical odds ratios (0.84) per 10 mg/dL for both targets; PCSK9 score associated with 6.1% higher diabetes risk.

3. Cholesterol Treatment Trialists' Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet. 2026;407(10529):689–703. PMID: 41655587 — 19 placebo-controlled trials, 123,940 participants; no causal relationship for 62 of 66 labelled undesirable effects.

4. Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–845 — almost 155,000 participants; 14 of 15 muscle-symptom reports not attributable to the statin; no excess after year one.

5. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210–1222 — n=60; nocebo ratio 0.90; 30 of 60 participants restarted statin therapy within six months.

6. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy (RACING). Lancet. 2022;400(10349):380–390. PMID: 35863366 — n=3,780; 3-year composite 9.1% vs 9.9%; non-inferior with fewer intolerance-related discontinuations.

7. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353–1364 — n=13,970; LDL-C −21%; MACE-4 HR 0.87 (0.79–0.96); primary-prevention subgroup HR 0.70 (0.55–0.89).

8. Laffin LJ, Bruemmer D, Garcia M, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers (SPORT). J Am Coll Cardiol. 2023;81(1):1–12. PMID: 36351465 — n=190; rosuvastatin 5 mg lowered LDL-C 37.9%; red yeast rice and five other supplements no different from placebo.

9. Commission Regulation (EU) 2022/860 amending Annex III to Regulation (EC) No 1925/2006 as regards monacolins from red yeast rice. Official Journal of the European Union, L 151, 2 June 2022 — daily portions restricted to below 3 mg of total monacolins; EFSA (2018) confirmed monacolin K lactone is identical to lovastatin. Member states voted on 13 May 2026 to prohibit monacolins in food supplements outright.

10. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol/ Circulation. Published online 13 March 2026 — restores LDL-C and non-HDL-C goals; Class I statin threshold lowered to 5% ten-year risk; ezetimibe, bempedoic acid and PCSK9 inhibitors as add-on options; inclisiran outcomes pending.

© 2026 FrontWave Media Ltd · Longevity Latest